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Introduction
Hepatic encephalopathy (HE) is a neuropsychiatric
syndrome related to liver damage or portal-systemic
anastomosis,1 but the exact mechanism remains ob-
scure. The influences of nitric oxide (NO) on hepatic
and brain injury are controversial, mainly derived from
its diverse functions: NO may be protective or toxic at
various concentrations, and its synthesis by NO syn-
thase (NOS) is under delicate control.2 Regarding the
influences on the brain, NO may be implicated in vas-
cular and blood-brain barrier permeability regulation.3
It contributes to hemodynamic changes in the brain
and also to the pathogenesis of acute hepatic failure-
related cerebral edema.4 In the liver, intrinsic hepatic
NO generation attenuates sinusoidal perfusion failure
and improves liver tissue oxygenation, thus limiting
hepatocyte injury during early reperfusion after hepatic
low-flow ischemia.5 In addition, NO donors amelio-
rated apoptotic liver damage6 or ischemia/reperfusion
(I/R) injury,7 and non-selective NOS inhibitors in-
creased mortality and decreased tissue perfusion during
endotoxemia.8 In contrast, excessive NO production can
be detrimental since it may downregulate cytochrome
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P450, suppress liver protein and DNA synthesis, then
induce apoptosis and necrosis.9 NO also reacts with su-
peroxide radical to form peroxynitrite, a potent oxidant
that inhibits cellular respiration and triggers apoptosis.10
Supplementation of the NO precursor L-arginine even
exacerbated acetaminophen-induced hepatotoxicity in
rats.11
It has been shown that NG-nitro-L-arginine methyl
ester (L-NAME), a non-selective NOS inhibitor aggra-
vated HE and increased mortality in rats with thioace-
tamide (TAA)-induced acute hepatic failure.12 Based
on elevated serum levels of bilirubin, alanine amino-
transferase (ALT), endotoxin, and tumor necrosis 
factor-α (TNF-α) after L-NAME administration, the
worsened HE was ascribed to aggravated liver damage
by non-selective NO inhibition.12 However, the plasma
nitrate/nitrite level, which represents the amount of
NO generation, was similar between L-NAME and
control groups.12 Since NO acts in an autocrinic/
paracrinic manner in that the blood nitrate/nitrite level
might not actually reflect the amount of hepatic NO
synthesis and the expression of different NOS iso-
enzymes in liver during HE was not clear, we conducted
this study to survey the molecular basis by which iso-
enzyme plays a major regulatory role in TAA-treated rats
with fulminant hepatic failure and HE.
Methods
Animal model
Male Sprague-Dawley rats (300–350 g) were caged at
24°C, with a 12-hour light-dark cycle and free access to
food and water until the time of the experiments. Ful-
minant hepatic failure was induced by intraperitoneal
injection of TAA (350 mg/kg in normal saline; Sigma
Chemical Co., St Louis, MO, USA) every 24 hours
for 3 consecutive days (n = 14). Rats treated with nor-
mal saline were categorized as controls (n = 14). To
avoid hypoglycemia and electrolytes imbalance,13 10%
glucose water mixed with lactate ringer (25 mL/kg)
was injected subcutaneously every 12 hours after the
first injection of TAA. Motor activities were measured
3 days after the first administration of TAA. Heparin-
ized blood samples were obtained afterwards from the
inferior vena cava for ALT, aspartate aminotrans-
ferase (AST), alkaline phosphatase, and bilirubin mea-
surements. The liver was dissected and removed for
reverse transcription–polymerase chain reaction (RT-
PCR) and Western blot analysis. The experiments were
conducted according to the American Physiological
Society guidelines for the care and use of laboratory
animals.
Measurement of motor activities
Motor activities were determined using the Opto-
Varimex animal activity meter (Columbus Instruments
Inc., Columbus, OH, USA).14 The sensors utilize high-
intensity, modulated infrared light beams to detect
motion. Animals were housed in transparent cages
(17 × 17 × 8 inches) through which 30 infrared beams
pass in the horizontal plane, 15 on each axis. This device
differentiates non-ambulatory movements (scratching,
gnawing) from ambulation on the basis of consecu-
tive interruption of the infrared monitoring beams.
An additional row of infrared beams in the horizontal
plane (15 on each axis) about 10 cm above the floor
was used to count the vertical movements. During the
measurements, animals had no access to food or chow.
All studies were performed under strictly standardized
conditions in the dark room for 30 minutes. The count
numbers of total, ambulatory, and vertical movements
were recorded to reflect the motor activities.
RNA isolation, RT and PCR
Hepatic total RNA was extracted with the RNeasy
Mini Kit (Qiagen GmbH, Hilden, Germany). A 1-step
RT-PCR kit (Qiagen GmbH) was used with the fol-
lowing components: 10 μL RT-PCR buffer containing
Tris-HCl, KCl, (NH4)2SO4 and 2.5 mmol/L MgCl2;
2 μL deoxynucleotide mixture containing 400 μmol/L
dATP, dCTP, dGTP and dTTP, respectively; 2 μL
enzyme mixture containing Omniscript™ reverse
transcriptase, Sensiscript™ reverse transcriptase, and
HotStar Taq™ DNA polymerase; 1 μL RNase inhibitor
(40 U); 3 μL of each random primer (10 pmol/μL),
and 1 μg substrate RNA. RNase-free water was added
in each reaction to the final volume of 50 μL. The 
sequences of the primers for eNOS were 5′-TACGGA-
GCAGCAAATCCAC-3′ (sense) and 5′-CAGGCTG-
CAGTCCTTTGATC-3′ (antisense), respectively. Those
for iNOS were 5′-CCCTTCCGAAGTTTCTGGCA-
GCAG-3′ (sense) and 5′-GGGCTCCTCCAAGGTG-
TTGCCC-3′ (antisense), respectively. A constitutively
expressed gene, β-actin, was analyzed as control, and
the primers were 5′-TTGTAACCAACTGGGACGA-
TATGG-3′ (sense) and 5′-GATCTTGATCTTCATG-
GTGCTAGG-3′ (antisense), respectively. A negative
control was included in each set of experiments.
The tubes were placed in a thermocycler (Biometra®
T Gradient thermocycler; Biometra GmbH, Göttingen,
Germany) at 50°C for 30 minutes for reverse tran-
scription, 95°C for 15 minutes for initial denaturation,
followed by 35 cycles of the following sequential steps:
30 seconds at 94°C (denaturation), 45 seconds at
57.2°C for eNOS, 62°C for iNOS, 59.6°C for β-actin
(annealing), and 45 seconds at 72°C (extension). The
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final extension was performed at 72°C for 10 minutes.
The primers for eNOS, iNOS and β-actin were
designed to allow amplification of 819, 473 and 764
base-pair fragments, respectively.15–17 Then, 10 μL of
the PCR-amplified mixture was subjected to electro-
phoresis on 1.5% agarose gel and visualized by ethid-
ium bromide staining. Location of the predicted PCR
products was confirmed by a 100-base pair ladder
(GIBCO BRL, Gaithersburg, MD, USA). The gel was
then photographed and the signal intensity quanti-
tated by a digitalized software (Kodak Digital Science™
ID Image Analysis Software; Eastman Kodak Co.,
Rochester, NY, USA). The index of eNOS and iNOS
signals were standardized against that of the β-actin signal
from the same RNA sample and expressed as eNOS/
β-actin and iNOS/β-actin ratios for comparison.
Western blot analysis
Livers were immediately frozen in liquid nitrogen and
stored at −80°C until required. The protein extracts
were made by pulverization in a grinder with liquid
nitrogen, then using a ratio of 1 mL lysis buffer for
each 100 mg powdered liver sample. The lysis buffer
consisted of phosphate-buffered solution containing 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), and 0.05% protease inhibitor
cocktail solution (Roche Diagnostics GmbH, Penzberg,
Germany). Protein concentration was determined for
each sample by the Bradford method.18 An aliquot of
20–40 μg protein from each sample that dissolved in
sample buffer (63mmol/L Tris-HCL, pH 6.8, contain-
ing 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, and
0.005% bomphenol blue) and 10 μg positive control
were separated on denaturing SDS-10% polyacrylamide
gels by electrophoresis (Mini-PROTEAN® 3 Cell; Bio-
Rad Laboratories, Hercules, CA, USA).
Prestained protein markers (SDS-PAGE Standards;
Bio-Rad Laboratories) were used for molecular weight
determinations. The positive controls included human
aortic endothelial cell lysate (1mg/mL) for eNOS, and
mouse macrophages (RAW 264.7) stimulated with
10ng/mL interferon-γ and 1 μg/mL LPS for 12 hours
(1 mg/mL) for iNOS (BD Transduction Laboratories,
BD Biosciences Pharmingen, USA). Proteins were then
transferred to a polyvinylidene difluoride membrane
(Immum-Blot™ PVDF Membrane; Bio-Rad Labora-
tories) by a semidry electroblotting system (Trans-Blot®
SD Semidry Electrophoretic Transfer Cell; Bio-Rad
Laboratories) for 1.5 hours at 4°C. To block nonspecific
binding, membranes were blocked for 30 minutes with
3% non-fat dry milk in TBS-T, pH 7.4 (25 mmol/L;
Tris base, 137 mmol/L; NaCl 2.7 mmol/L; KCL, 1%
Tween 20).
Blots were incubated with the first antibody, anti-
eNOS, (1:2000) and anti-iNOS monoclonal antibod-
ies (1:1000), diluted with 3% non-fat dry milk in TBS-T
for 90 minutes at room temperature and washed. Then,
the blots were incubated for 90 minutes with the sec-
ondary antibody (horseradish peroxidase-conjugated
goat anti-mouse IgG antibody, diluted with 3% non-
fat dry milk in TBS-T; Sigma Chemical Co.) and
washed. Subsequent detection of the specific proteins
(140 kDa for eNOS, 130 kDa for iNOS) was per-
formed by enhanced chemiluminescence (BCIP/NBT
Solution; Amresco Co., Ohio, USA). With a computer-
assisted video densitometer and digitalized software
(Kodak Digital Science™ ID Image Analysis Software,
Eastman Kodak Co.), the blots were scanned, pho-
tographed, and then the signal intensity (integral vol-
ume) of the appropriate bands was analyzed.
Drugs
TAA was purchased from Sigma Chemical Co.
(St Louis, MO, USA).
Statistical analysis
All results are expressed as mean ± standard error of the
mean. Statistical analyses were performed using inde-
pendent t test and bivariate correlation with Pearson’s
test, accordingly. Results were considered statistically
significant at p < 0.05.
Results
Motor activities
The motor activities of the control and TAA groups
are shown in Figure 1. The TAA group showed lower
motor activity counts than the control group in total
(TAA vs. control, 418 ± 88 vs. 2515 ± 356 counts/
30 min, p < 0.001), ambulatory (186 ± 61 vs. 1523 ±
267counts/30 min, p <0.001), and vertical movements
(40 ± 15 vs. 398 ± 92 counts/30 min, p = 0.002).
Plasma ALT, AST, alkaline phosphatase and
total bilirubin
Plasma concentrations of ALT (TAA vs. control, 196 ±
24 vs. 33 ± 2 U/L, p < 0.001), AST (542 ± 53 vs. 93 ±
6 U/L, p < 0.001), alkaline phosphatase (241 ± 12 vs.
160 ± 11 U/L, p < 0.001), and bilirubin (1.1 ± 0.3 vs.
0.1 ± 0.0 mg/dL, p = 0.003) were all higher in the TAA
group than in the control group.
Analysis of NOS expression
Semi-quantitative RT-PCR of hepatic eNOS expres-
sion was higher in the TAA group than in the control
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group (Figure 2). The mean intensity of eNOS signal
standardized against that of β-actin signal (eNOS/
β-actin) in the TAA group vs. the control group was
0.79 ± 0.07 vs. 0.45 ± 0.04 (p=0.001). However, iNOS
expression (iNOS/β-actin, 0.30 ± 0.05 vs. 0.21 ± 0.04,
p = 0.148) was similar between the 2 groups.
Western blot analysis
In the control group, Western blot of liver homo-
genates revealed a single band at 140 kDa stained with
anti-eNOS antibody and a very faint band at 130 kDa
stained with anti-iNOS antibody (Figure 3). In the
TAA group, eNOS protein expression was 1.8-folds
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Figure 1. Mean and individual values of motor activity counts in TAA
and control groups. (A) Total, (B) ambulatory and (C) vertical move-
ments were all significantly decreased in the TAA group.
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Figure 2. (A, B) Representative agarose gel electrophoresis of iNOS and eNOS cDNA in the liver of control and TAA-treated rats.
Marker = 100-bp DNA ladder; iNOS = 473 bp; eNOS = 819 bp; bp = base pairs. (C, D) Semi-quantitative RT-PCR analysis of iNOS and
eNOS expression.
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higher than in the control group (TAA vs. control,
0.63 ± 0.07 vs. 0.35 ± 0.05 [relative optical density],
p = 0.002), whereas iNOS protein expression was not
significantly different between TAA and control rats
(0.13 ± 0.05 vs. 0.12 ± 0.04, p = 0.853).
Correlations between severity of hepatic injury,
HE and hepatic eNOS expression
Plasma concentrations of ALT, AST and bilirubin
showed negative correlations with total movements,
indicating that more severe liver damage was associated
with aggravated HE. Hepatic eNOS mRNA expres-
sion was negatively correlated with total movements
and positively correlated with ALT, AST and biliru-
bin. In addition, liver eNOS protein showed positive
correlations with ALT, AST and bilirubin, suggesting
that hepatic injury and HE are accompanied by eNOS
mRNA and protein upregulation (Table 1, Figure 4).
Discussion
NO plays a distinct role in the pathogenesis of HE.
Excessive NO formation in portal hypertensive states
leads to vasodilatation,19 which may participate in the
development of HE.20 Cerebral vasculature dilatation
increases capillary surface area and facilitates the dif-
fusion of ammonia.21 In addition, cerebral blood flow
autoregulation defect was found in fulminant hepatic
failure.22 These conditions can be responsible for
brain swelling and intracranial hypertension in hepatic
coma. A retrospective study also revealed a strong
relationship among cerebral blood flow, brain swelling,
outcome and depth of coma.23
According to our previous study, chronic L-NAME
administration aggravates liver injury, with detrimen-
tal effects on survival and HE in TAA-treated rats.12
Nω-nitro-L-arginine (L-NNA), another non-selective
NO inhibitor, also showed similar results in dimethyl-
nitrosamine-treated rats.24 NO has been known for its
effects on vasodilatation and platelet aggregation inhi-
bition: L-NNA aggravated I/R injury partly by vaso-
constriction with compromised hepatic blood flow25
and NO prevented hepatic microvascular shutdown
during endotoxemia.26 In a mouse model of immuno-
logic liver damage, NO also protects the liver through
vasodilatation and/or platelet aggregation inhibition.27
Among the NOS isoenzymes, iNOS inhibition resulted
in similar changes in sinusoidal perfusion and hepato-
cyte injury in rats that had hepatic reperfusion injury.5
These findings suggest the role of eNOS in protecting
the liver against various insults. In fact, constitutive
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Figure 3. (A, B) Representative Western blots of iNOS (130 kDa) and eNOS (140 kDa) protein in the liver of control and TAA-treated rats.
M = marker; C = control group; T = TAA group; P = positive control. (C, D) Semi-quantitative analysis of iNOS and eNOS protein expression
in the liver using densitometric units.
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NOS (cNOS) inhibition aggravated I/R- or endotoxin-
related liver injury.5,28 An increase of I/R-induced
liver injury was also demonstrated in mice genetically
deficient in eNOS.29
In the current study, enhanced hepatic eNOS
mRNA expression and protein synthesis in rats with
TAA-induced fulminant hepatic failure and HE were
noted. Of interest, they showed negative correlations
with total movements and positive correlations with
plasma ALT, AST and bilirubin levels. In addition,
negative correlations between total movements and
ALT, AST, and bilirubin were found, compatible with
Table 1. Correlation coefficients (r) and p values between total movements, liver biochemistry parameters, and mRNA and protein
expression of hepatic eNOS
Total movements ALT AST Bilirubin eNOS protein
eNOS mRNA
r −0.543 0.543 0.514 0.321 0.056
p 0.003 0.003 0.005 0.096 0.777
eNOS protein
r −0.324 0.533 0.447 0.424
p 0.093 0.004 0.017 0.025
ALT
r −0.589
p 0.001
AST
r −0.614
p 0.001
Bilirubin
r −0.543
p 0.015
ALT = alanine aminotransferase; AST = aspartate aminotransferase.
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the hypothesis that more severe liver injury is associ-
ated with more severe HE. One may debate the actual
role of hepatic eNOS: if enhanced hepatic eNOS activ-
ity is harmful, it would be accompanied by higher
ALT, AST and bilirubin concentrations and lower
movement counts. However, the assumption is con-
tradictory to recent studies on NOS inhibitors,5,12,24,28
which showed that eNOS inhibition led to detrimental
effects on hepatic injury or, additionally, HE. Therefore,
the inverse might be inferred: after TAA administration,
hepatic damage and HE are accompanied by eNOS up-
regulation in the liver. In addition, the more severe the
liver damage and HE, the higher the hepatic eNOS
expression, suggesting molecular evidence of NO 
modulation by eNOS during fulminant hepatic failure
and HE. Though there was no significant correlation
between eNOS mRNA and protein levels, the condi-
tion might be attributed to the following factors: first,
the involvement of post-transcriptional and post-
translational regulators; second, the liver was harvested
at the same time for both mRNA and protein assay.
Therefore, eNOS mRNA or even protein might have
undergone various degrees of degradation at the time
of analysis (however, as compared with the control
group, eNOS mRNA and protein in TAA-administered
rats did show significantly enhanced expressions).
No significant changes in hepatic iNOS mRNA and
protein expression were identified in this study. Similar
to our findings, iNOS mRNA upregulation was not
detected in the post-ischemic liver of mice and iNOS
inhibition did not exacerbate post-ischemic liver injury.30
In mice with genetic iNOS deficiency, they also suffered
from similar LPS-induced liver damage in comparison
with wild-type mice.31 These observations suggest that
iNOS-derived NO does not play a significant role in
hepatic damage. However, contradictory results have
been reported: iNOS inhibition exerted beneficial effects
on reperfusion liver injury in pigs.32 Furthermore,
iNOS even protected the liver against LPS-induced
apoptotic damage.33 The paradoxical and dual effects
may be attributed to a great variety of inhibitors, dos-
ages and experimental designs. Considering the similar
studies on TAA-induced liver injury, it has been found
that aminoguanidine pretreatment markedly diminished
injury severity by decreasing oxidative stress and lipo-
peroxidation.34 Aminoguanidine pretreatment also
significantly reduced the severity of TAA (500 mg/kg,
2 intraperitoneal injections, 8 hours apart)-induced
hepatic damage and improved mortality.35 However, the
beneficial effect might not be attributed to iNOS inhi-
bition by aminoguanidine, since iNOS mRNA is only
detected in the post-necrotic proliferative hepatocytes34
and guanidines can even scavenge peroxynitrite.36
Furthermore, TAA 350 mg/kg injections once per day
for 3 consecutive days were used in the current study,
with a lower dose, a longer dosing interval and different
evaluation time as compared with the previous study.35
In fact, the same group reported a mortality of 75%,37
which is much higher than the 18% mortality in our
previous study.16 Therefore, the degree and onset of
hepatic injury do vary and may have different influences
on iNOS expression.
From previous studies of NOS inhibitors and the
current study on hepatic NOS isoforms in rats that
have undergone TAA-induced hepatic damage and HE,
eNOS may be a remarkable modulator of acute hepatic
injury, although NO may at the same time aggravate
HE. Further tests on the optimal dose and timing of
eNOS inhibition to ameliorate HE without compro-
mising the hepatic NO level required to maintain liver
homeostasis may have potential in the management
of acute liver failure and HE.
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